FDA approves Pfizer’s HRR mCRPC drug
June 21, 2023Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer
US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …
PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US
June 21, 2023Medical Communications Ketamine, Neurology, PharmaTher, Vitruvias, commercialisation
Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to bring Ketarx products to the …
Sirnaomics advances isSCC candidate into late-stage clinical development
June 20, 2023Research and Development FDA, Oncology, Sirnaomics, clinical trial, isSCC
Global RNA therapeutics biopharmaceutical company Sirnaomics has announced that it has advanced its Squamous Cell Carcinoma in situ (isSCC) candidate …
Abu Dhabi’s Department of Health, M42 and AbbVie enter strategic partnership
June 20, 2023Medical Communications AbbVie, Abu Dhabi, DoH, M42, Oncology, strategic partnership
Abu Dhabi’s Department of Health (DoH) has signed a Memorandum of Understanding (MoU) with AbbVie and M42 to advance research …
GSK announces extension of FDA’s review for momelotinib
June 20, 2023Medical Communications FDA, GSK, Oncology, momelotinib, new drug application
GSK has announced that the US Food and Drug Administration (FDA) has extended its review period for the new drug …
Santhera and Catalyst Pharmaceuticals sign $231m license and collaboration deal
June 20, 2023Medical Communications Catalyst Pharmaceuticals, Rare Diseases, Vamorolone, licence and collaboration, santhera
Swiss specialty pharmaceutical company Santhera and US-based biopharmaceutical company Catalyst Pharmaceuticals have announced that they have signed an exclusive license …
Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer
June 20, 2023Immodulon, Josefine Roemmler-Zehrer, appointment, chief medical officer
Cancer immunotherapy company Immodulon has announced that it has appointed Josefine Roemmler-Zehrer as chief medical officer, bringing with her vast …
Scientists develop 3D printed pills for time-controlled release
June 19, 2023Research and Development 3d printed pills, 3d printing, Max Planck Insititute, Pharmacy, University of California
A team of scientists at the Max Planck Institute (MPI) for Informatics, Germany, and the University of California, US, have …
Vaxxas opens manufacturing facility for needle-free vaccine patch
June 19, 2023Research and Development Immunology, Vaxxas, manufacturing, needle-free vaccines, vaccines
Clinical stage biotech company Vaxxas has announced that it is opening a biomedical manufacturing facility in Brisbane, Australia, for the …
ImmuPharma initiates phase 2/3 clinical trial for lupus treatment
June 19, 2023Research and Development Avion Pharmaceuticals, ImmuPharma, Immunology, Lupus, clinical trial
ImmuPharma has announced that it will commence a phase 2/3 adaptive clinical trial of P140 (Lupuzor) in patients with systemic …
Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically
June 19, 2023Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics
US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …
LEO Pharma appoints Leanne Walsh as general manager and vice president for UK and Ireland
June 19, 2023LEO Pharma, appointment, general manager, vice president
Medical dermatology company LEO Pharma has announced that it has appointed Leanne Walsh as its new general manager and vice …
Nordic Bioscience receives FDA Letter of Support for biomarker in aggressive tumour fibrosis
June 16, 2023Research and Development FDA, Nordic Bioscience, Oncology, Roche, tumour fibrosis
Danish biomarker company Nordic Bioscience has announced that the US Food and Drug Administration (FDA) has awarded it a Letter …
Takeda and HUTCHMED’s cancer drug shown to prolong overall survival
June 16, 2023Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …
FDA gives Eagle Pharmaceuticals Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for SCABP drug
June 15, 2023Research and Development Eagle Pharmaceuticals, FDA, FDA fast-track, Immunology, SCABP
US-based pharmaceutical company Eagle Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted its severe community-acquired …
Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
June 15, 2023Research and Development Astellas, Cullgen, Oncology, protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …
Critical Path Institute receives FDA Biomarker LOS for DIPI biomarkers
June 14, 2023Research and Development Critical Path Institute, Endocrinology, FDA, biomarkers, pancreatic injury
US-based Critical Path Institute (C-Path) has announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and …
Kymera Therapeutics reports positive data in cancer drug trials
June 14, 2023Research and Development Cancer, Kymera Therapeutics, Oncology, autoimmune diseases, clinical trials, inflammatory diseases
US clinical-stage biopharmaceutical company Kymera Therapeutics has shared new data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …
AstraZeneca’s breast cancer drug given Priority Review by FDA
June 13, 2023Business Services AstraZeneca, FDA, Oncology, breast cancer
UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …
Novo Nordisk invests DKK 15.9bn to expand API production in Denmark
June 13, 2023Manufacturing and Production APIs, Chronic Diseases, Novo Nordisk, chronic diseases
Danish healthcare company Novo Nordisk has announced that it will invest another DKK 15.9bn into expanding an existing Active Pharmaceutical …
Latest content
FibroFind appoints Lee Borthwick as CEO
